Talquetamab (Talvey)

Key Messages

• Canada’s Drug Agency (CDA-AMC) recommends that Talvey not be reimbursed by public drug plans for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 3 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody (mAb), and who have demonstrated disease progression on or after the last therapy.
• Evidence from 1 clinical study showed that Talvey may improve treatment response rates in adults with RRMM who have received at least 3 prior lines of therapy. However, no causal conclusions could be drawn about the effect of Talvey on the outcomes important to patients and clinicians (e.g., progression-free survival and overall survival) based on the weak evidence from 1 noncomparative clinical trial.
• The evidence is insufficient to determine whether Talvey meets patient needs for effective, accessible, and portable treatment options that can extend life, delay worsening or spreading of disease, improve quality of life, and reduce side effects.
• Talvey’s adverse effect profile may not align with patient values regarding side effects. Notably, dysgeusia — an unfavourable side effect from the patient perspective — was 1 of the most frequently reported adverse events with Talvey in the submitted clinical trial. Other frequently reported side effects may be considered unfavourable by patients, as the patient group input reported infections and nail, skin, and oral issues as the least bearable side effects.